In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve.
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16
Atopic dermatitis is an inflammatory, itchy skin condition characterised by a fluctuating
and chronic disease course. Effective therapies inhibit downstream immune signalling
of interleukin (IL)-4, IL-13, IL-31,1 and Janus kinase activity.2 Biologics that target
upstream cytokines, such as IL-1α, IL-33, and thymic stromal lymphopoietin (TSLP),
have so far been unsuccessful. OX40, a cell-surface glycoprotein, which is highly
expressed on T cells and dendritic cells in lesional atopic dermatitis skin, works
downstream of TSLP; OX40 stimulates proliferation and survival of activated T cells,
some of which might become memory T cells.
This article briefly explores the natural pH of skin and health implications as pH levels fluctuate; factors considered include the microbiome, topical products, acidification, buffering and more.
Akari Therapeutcis (AKTX) Reports Publication of Phase II Data of Investigational Nomacopan streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.